Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
Abstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positi...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2023-09-01
|
| Colección: | Cancer Imaging |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s40644-023-00608-0 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|